

Set	Items	Description
S1	14	CYSLOSPORIN
S2	401705	TOPICAL
S3	1397863	WOUND? ? OR BURN? ? OR FISSURE? ?
S4	143419	CYCLOSPORIN
S5	300	S2(S)S3(S)S4
S6	107	S5 NOT PY>1998
S7	1418	DEXPANTHENOL
S8	0	S6 AND S7
S9	104	RD S6 (unique items)
S10	242	S7 AND S3
S11	93	S7(S)S3
S12	31	S11 NOT PY>1998
S13	26	RD (unique items)

February 5, 2004

13/6/1 (Item 1 from file: 155)
07220159 92082656 PMID: 1747245

Normal wound healing of the paranasal sinuses: clinical and experimental investigations.
1991

13/6/2 (Item 2 from file: 155)
06995805 91236467 PMID: 2032874

[Experimental studies of wound healing in the paranasal sinuses. II. Spontaneous wound healing and drug effects in a standardized wound model]
Experimentelle Untersuchungen zur Wundheilung in den Nasennebenhöhlen. II. Spontaner Wundschluss und medikamentöse Effekte im standardisierten Wundmodell.
Feb 1991

13/6/3 (Item 1 from file: 5)
0011231812 BIOSIS NO.: 199800026059

Improvement in the healing rate of radiation-induced wounds using a topical formulation containing GLA, vitamin E and dexpanthenol
1997

13/6/4 (Item 1 from file: 34)
04263211 Genuine Article#: RR631 Number of References: 0

Title: CONTACT ALLERGY TO DEXPANTHENOL - A REPORT OF 7 CASES AND REVIEW OF THE LITERATURE (Abstract Available)

13/6/5 (Item 2 from file: 34)
00837159 Genuine Article#: EZ509 Number of References: 0

Title: EXPERIMENTAL INVESTIGATIONS ON WOUND-HEALING OF THE PARANASAL SINUSES .2. SPONTANEOUS WOUND CLOSURE AND PHARMACOLOGICAL EFFECTS IN A STANDARDIZED ANIMAL-MODEL (Abstract Available)

13/6/6 (Item 1 from file: 73)
07521263 EMBASE No: 1998423759

Effect of Bepanthen(R) Ointment on the graft-donor site wound-healing model: Double-blind biometrological and clinical study, with assessment by the patient, versus the vehicle

EFFET DE BEPANTHENE(R) ONGUENT SUR LE MODELE DE CICATRISATION DU SITE DE PRELEVEMENT DE GREFFE: ETUDE BIOMETROLOGIQUE, CLINIQUE ET EVALUATION PAR LE PATIENT, EN DOUBLE AVEUGLE CONTRE VEHICULE
1998

13/6/7 (Item 2 from file: 73)
06938539 EMBASE No: 1997223043

A double-blind biometrological, histological, clinical and patient evaluation pilot study of the effect of Bepanthen(R) Ointment versus excipient using a skin graft donor site as a wound healing model

ETUDE PILOTE BIOMETROLOGIQUE, HISTOLOGIQUE, CLINIQUE ET EVALUATION PAR LE PATIENT, EN DOUBLE AVEUGLE CONTRE EXCIPIENT, DE L'EFFET DE BEPANTHENE(R) ONGUENT SUR LE MODELE DE CICATRISATION DU SITE DE PRELEVEMENT DE GREFFE
1997

13/6/8 (Item 3 from file: 73)
06044432 EMBASE No: 1995074701

Efficacy of dexpanthenol in wound healing: Double-blind assessment of excised wound tissue by ultrasound and histologic examination
1995

13/6/9 (Item 1 from file: 340)
2740154
C/SKIN-TEAR MEDICAMENT AND METHOD OF USE; TOPICAL OINTMENT

13/6/10 (Item 1 from file: 342)
01419272 WPI Acc No: 94-333993/42
Medicament for wounds and skin, hair and stomach ailments...

13/6/11 (Item 1 from file: 349)
00308042
ALLANTOIN-METAL COMPLEXES FOR SKIN AND HAIR
COMPLEXES ALLANTOINE-METAUX POUR LA PEAU ET LES CHEVEUX
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 6007
Publication Year: 1995

13/6/12 (Item 2 from file: 349)
00198699
COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF DAMAGED OR DISEASED TISSUE
COMPOSITION ET PROCEDE DE TRAITEMENT LOCAL DE TISSUS ABIMES OU MALADES
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 8060
Publication Year: 1991

13/6/13 (Item 1 from file: 654)
4074969
Derwent Accession: 1999-034074
Utility
C/ X-ray induced skin damage protective composition
; COMPOSITION COMPRISING SELENOAMINO ACID, GLUTATHIONE, EPIDERMAL GROWTH
FACTOR AND/OR FIBROBLAST GROWTH FACTOR IN CARRIER FOR TOPICAL APPLICATION

Fulltext Word Count: 6116
Number of Claims: 2
Exemplary or Independent Claim Number(s): 1
Number of US cited patent references: 1

13/6/14 (Item 2 from file: 654)
4026505
Derwent Accession: 1998-051883
Utility
C/ DHA-pharmaceutical agent conjugates of taxanes
; ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIAN CANCERS

Fulltext Word Count: 15457
Number of Claims: 12
Exemplary or Independent Claim Number(s): 1
Number of Drawing Sheets: 14
Number of Figures: 27
Number of US cited patent references: 25
Number of non-US cited patent references: 12
Number of non-patent cited references: 26

13/6/15 (Item 3 from file: 654)
3934627

Derwent Accession: 1993-368376

Utility

**C/ Method for treating skin wrinkles
; PANTHENOL, ACNE**

Fulltext Word Count: 5280

Number of Claims: 2

Exemplary or Independent Claim Number(s): 1

Number of US cited patent references: 11

Number of non-US cited patent references: 1

Number of non-patent cited references: 2

13/6/16 (Item 4 from file: 654)

3887011

Derwent Accession: 1997-478864

Utility

**C/ X-ray induced skin damage protective composition
; MIXTURE OF SELENOMETHIONINE AND GLUTATHIONE TO PREVENT SKIN DAMAGE FROM
RADIATION THERAPY**

Fulltext Word Count: 6489

Number of Claims: 17

Exemplary or Independent Claim Number(s): 1,11

Number of US cited patent references: 22

13/6/17 (Item 5 from file: 654)

3826545

Derwent Accession: 1993-368376

Utility

**C/ Method for treating acne
; USING SALICYLIC ACID AND PANTOTHENIC AGENTS OR DERIVATIVES FOR SKINS**

Fulltext Word Count: 5818

Number of Claims: 18

Exemplary or Independent Claim Number(s): 1

Number of US cited patent references: 10

Number of non-US cited patent references: 2

Number of non-patent cited references: 2

13/6/18 (Item 6 from file: 654)

3775901

Derwent Accession: 1996-476259

Utility

**C/ Wound cleanser method of use
; MIXTURE OF ALOA VERA AND HYDROXYQUINOLINE**

Fulltext Word Count: 2352

Number of Claims: 13

Exemplary or Independent Claim Number(s): 1

Number of US cited patent references: 6

Number of non-patent cited references: 1

13/6/19 (Item 7 from file: 654)

3754235

Derwent Accession: 1996-392065

Utility

**C/ Dermatological compositions and method of treatment of skin lesions
therewith using benzoyl peroxide and tocopherol esters
; ANTIACNE AGENTS**

Fulltext Word Count: 7783

Number of Claims: 8

Exemplary or Independent Claim Number(s): 1,4,7,8
Number of US cited patent references: 1
Number of non-patent cited references: 2

13/6/20 (Item 8 from file: 654)
3744472
Derwent Accession: 1996-341447
Utility
C/ Skin-tear medicament and method of use
; TOPICAL OINTMENT

Fulltext Word Count: 3539
Number of Claims: 18
Exemplary or Independent Claim Number(s): 1
Number of US cited patent references: 2
Number of non-patent cited references: 1

13/6/21 (Item 9 from file: 654)
3643976
Derwent Accession: 1995-310868
Utility
C/ Dermatological compositions and method of treatment of skin lesions
therewith
; BENZOYL PEROXIDE AND A COMPOUND FOR REDUCING SKIN IRRITATION ASSOCIATED
WITH IT

Fulltext Word Count: 7698
Number of Claims: 9
Exemplary or Independent Claim Number(s): 1,7
Number of US cited patent references: 8
Number of non-US cited patent references: 9

13/6/22 (Item 10 from file: 654)
3610984
Derwent Accession: 1988-001747
Utility
C/ New esters of alginic acid

Fulltext Word Count: 20783
Number of Claims: 9
Exemplary or Independent Claim Number(s): 1
Number of US cited patent references: 29
Number of non-US cited patent references: 15
Number of non-patent cited references: 6

13/6/23 (Item 11 from file: 654)
3522660
Derwent Accession: 1988-001747
Utility
C/ Esters of alginic acid

Fulltext Word Count: 21153
Number of Claims: 17
Exemplary or Independent Claim Number(s): 1
Number of US cited patent references: 52
Number of non-US cited patent references: 18
Number of non-patent cited references: 112

13/6/24 (Item 12 from file: 654)
3518388
Derwent Accession: 1992-357786

Utility
C/ Partial esters of gellan
; WITH AN ARALIPHATIC ALCOHOL HAVING A BENZENE RING

Fulltext Word Count: 15339
Number of Claims: 3
Exemplary or Independent Claim Number(s): 1
Number of US cited patent references: 3
Number of non-US cited patent references: 3
Number of non-patent cited references: 8

13/6/25 (Item 13 from file: 654)
3442332
Derwent Accession: 1988-001747
Utility
C/ Esters of alginic acid with steroidal alcohols
; VEHICLES FOR DRUGS, SURGICAL SUTURES, SKIN SUBSTITUTES

Fulltext Word Count: 20548
Number of Claims: 3
Exemplary or Independent Claim Number(s): 1
Number of US cited patent references: 49
Number of non-US cited patent references: 15
Number of non-patent cited references: 8

13/6/26 (Item 14 from file: 654)
3313260
Derwent Accession: 1988-001747
Utility
C/ Esters of alginic acid
; SANITARY OR SURGICAL ARTICLE

Fulltext Word Count: 20659
Number of Claims: 8
Exemplary or Independent Claim Number(s): 1
Number of US cited patent references: 10
Number of non-patent cited references: 106
?

13/3,AB,K/3 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0011231812 BIOSIS NO.: 199800026059

Improvement in the healing rate of radiation-induced wounds using a topical formulation containing GLA, vitamin E and dexpanthenol

AUTHOR: Flockhart I R (Reprint); Hopewell J W; Whittle B A

AUTHOR ADDRESS: Tokenspire Business Park, 3 Hull Road, Woodmansey, E. Yorks, UK**UK

JOURNAL: Journal of Pharmacy and Pharmacology 49 (SUPPL. 4): p66 Sept, 1997 1997

MEDIUM: print

CONFERENCE/MEETING: 134th Meeting of the British Pharmaceutical Conference Scarborough, England, UK September 15-18, 1997; 19970915

SPONSOR: The Royal Pharmaceutical Society of Great Britain

ISSN: 0022-3573

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

Improvement in the healing rate of radiation-induced wounds using a topical formulation containing GLA, vitamin E and dexpanthenol

13/3,AB,K/4 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2004 Inst for Sci Info. All rts. reserv.

04263211 Genuine Article#: RR631 Number of References: 0
(NO REFS KEYED)

Title: CONTACT ALLERGY TO DEXPANTHENOL - A REPORT OF 7 CASES AND REVIEW OF THE LITERATURE (Abstract Available)

Author(s): SCHMIDGREDELMEIER P; WYSS M; ELSNER P

Corporate Source: UNIV ZURICH,DEPT DERMATOL,GLORIASTR 31/CH-8091 ZURICH//SWITZERLAND/

Journal: DERMATOSEN IN BERUF UND UMWELT, 1995, V43, N4 (JUL-AUG), P175-178
ISSN: 0343-2432

Language: ENGLISH Document Type: REVIEW

Abstract: **Dexpanthenol** desires widespread use in medical and cosmetic applications for its **wound** -healing and cell growth stimulating activity. Nevertheless reports about contact dermatitis om **dexpanthenol** are rare in the literaure. We report seven cases of contact dermatitis, in which **dexpanthenol** was the causative agent and induced clinically relevant sensitizations. We also discuss other cases described in the literature. Contact sensitization to **dexpanthenol** is not frequent but mostly of clinical importance in encountered cases. We therefore propose to include **dexpanthenol** in the patch test series of externally applied medicaments.

Abstract: **Dexpanthenol** desires widespread use in medical and cosmetic applications for its **wound** -healing and cell growth stimulating activity. Nevertheless reports about contact dermatitis om **dexpanthenol** are rare in the literaure. We report seven cases of contact dermatitis, in which **dexpanthenol** was the causative agent and induced clinically relevant sensitizations. We also discuss other cases described in the literature. Contact sensitization to **dexpanthenol** is not frequent but mostly of clinical importance in encountered cases. We therefore propose to include **dexpanthenol** in the patch test series of externally applied medicaments.

13/3,AB,K/8 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

06044432 EMBASE No: 1995074701

Efficacy of dexpanthenol in wound healing: Double-blind assessment of excised wound tissue by ultrasound and histologic examination

Pugliese P.T.; Farina J.C.; Chautems Y.

Milmark Research Inc., Bernville, PA 19506 United States

Nouvelles Dermatologiques (NOUV. DERMATOL.) (France) 1995, 14/2
(130-138)

CODEN: NODEE ISSN: 0752-5370

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: FRENCH; ENGLISH

Pantothenic acid is known as a water soluble vitamin active in tissue repair. In a double blind clinical trial an alcohol analogue to pantothenic acid, **dexpanthenol**, was evaluated for its efficacy in improving the **wound** healing process in 15 adult male subjects. Four standardized epidermal shave **wounds** were produced in all subjects; three **wounds** were each treated daily for five days with either a water-in-oil emulsion with **dexpanthenol**, a water-in-oil emulsion, or a first aid cream. The fourth was an untreated control. Erythema, **wound** closure, **wound** volume, and viscoelasticity were assessed via ultrasound measurement and histologic analysis. Epidermal **wounds** treated with the **dexpanthenol** emulsion showed a reduction in erythema and a more elastic and more solid tissue regenerate. Histologically, in 10 of 15 subjects **dexpanthenol** proved to be effective in stimulating the healing process.

Efficacy of dexpanthenol in wound healing: Double-blind assessment of excised wound tissue by ultrasound and histologic examination

...in tissue repair. In a double blind clinical trial an alcohol analogue to pantothenic acid, **dexpanthenol**, was evaluated for its efficacy in improving the **wound** healing process in 15 adult male subjects. Four standardized epidermal shave **wounds** were produced in all subjects; three **wounds** were each treated daily for five days with either a water-in-oil emulsion with **dexpanthenol**, a water-in-oil emulsion, or a first aid cream. The fourth was an untreated control. Erythema, **wound** closure, **wound** volume, and viscoelasticity were assessed via ultrasound measurement and histologic analysis. Epidermal **wounds** treated with the **dexpanthenol** emulsion showed a reduction in erythema and a more elastic and more solid tissue regenerate. Histologically, in 10 of 15 subjects **dexpanthenol** proved to be effective in stimulating the healing process.

13/3,AB,K/9 (Item 1 from file: 340)

DIALOG(R) File 340:CLAIMS(R)/US Patent

(c) 2004 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 2740154 IFI Acc No: 9617546

Document Type: C

SKIN-TEAR MEDICAMENT AND METHOD OF USE; TOPICAL OINTMENT

Inventors: Mulder Gerit D (US)

Assignee: Unassigned Or Assigned To Individual

Assignee Code: 68000

Publication (No,Date), Applic (No,Date):

US 5536502 19960716 US 95383507 19950203

Publication Kind: A

Calculated Expiration: 20150203

Priority Applic(No,Date): US 95383507 19950203

Abstract: A low-sensitizing medicament for use in treating skin-tear injuries includes an emulsified water and hydrocarbon carrier portion, an emollient portion, a hydroxyquinoline antimicrobial portion, a mild keratolytic portion, and a paraben preservative portion. Additional ingredients include a zinc oxide topical protectant, vitamin E, a buffer or alkalizer agent that adjusts pH in a range from 6.5 to 6.8, and a scenting agent.

Non-exemplary Claims: ...18. A non-irritating medicament for use in treating skin-tear **wounds** , consisting essentially of: an emulsified carrier portion including water, aloe vera gel, and mineral oil...

...10% of the total medicament weight, said medicament being essentially free of sensitizing agents including **dexpantenol** , chlorides, and propylene glycol.

13/3,AB,K/10 (Item 1 from file: 342)
DIALOG(R) File 342:Derwent Patents Citation Indx
(c) 2004 Thomson Derwent. All rts. reserv.

01419272 WPI Acc No: 94-333993/42

Medicament for wounds and skin, hair and stomach ailments - contains alpha liponic acid and pantothenic acid or dexpantenol

Patent Assignee: (RABI/) RABIEN M

Author (Inventor): RABIEN M

Patent (basic)

Patent No	Kind	Date	Examiner	Field of Search
DE 4313428	A1	941027 (BASIC)	None	

Derwent Week (Basic): 9442

Priority Data: DE 4313428 (930426)

Applications: DE 4313428 (930426)

Derwent Class: B05

Int Pat Class: A61K-031/38

Number of Patents: 001

Number of Countries: 001

Number of Cited Patents: 000

Number of Cited Literature References: 000

Number of Citing Patents: 001

?

00214644

TOPICAL FORMULATION OF CYCLOSPORINE
FORMULATION TOPIQUE DE CYCLOSPORINE

Patent Applicant/Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,

Inventor(s):

HEWITT Charles W,

BLACK Kirby S,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9211860 A1 19920723

Application: WO 91US123 19910107 (PCT/WO US9100123)

Priority Application: WO 91US123 19910107

Designated States: AT AU BB BE BF BG BJ BR CA CF CG CH CM DE DK ES FI FR GA

GB GR HU IT JP KP KR LK LU MC MG ML MR MW NL NO RO SD SE SN SU TD TG

Publication Language: English

Fulltext Word Count: 11200

English Abstract

The present invention provides formulations for the **topical** application of **cyclosporin** to skin tissue for treatment of autoimmune, T-cell mediated immune disease, and inflammatory conditions, and for producing prolonged skin allograft survival and **wound** healing. In addition, methods for the use of said formulations -- in tandem with systemic applications of **cyclosporin** or without same -- are suggested. The present invention also suggests alternative formulations and delivery systems for the efficacious treatment of the aforementioned conditions, and further suggests a model with which formulations may be tested.

French Abstract

Cette invention concerne des formulations destinees a l'application topique de cyclosporine sur les tissus cutanes pour traiter les maladies auto-immunes, les maladies immunes a mediation par lymphocytes T, et les etats inflammatoires, et pour produire une plus longue survie de l'allogreffe cutanee et une meilleure cicatrisation. En outre, cette invention propose des procedes d'utilisation desdites formulations - associees ou non a des applications systemiques de cyclosporine - ainsi que d'autres formulations et dispositifs d'administration permettant de traiter efficacement les etats pathologiques decrits precedemment, et un modele a l'aide duquel on peut tester lesdites formulations.

Fulltext Availability:

Detailed Description

Claims

English Abstract

The present invention provides formulations for the **topical** application of **cyclosporin** to skin tissue for treatment of autoimmune, T-cell mediated immune disease, and inflammatory conditions, and for producing prolonged skin allograft survival and **wound** healing. In addition, methods for the use of said formulations -- in tandem with systemic applications of **cyclosporin** or without same -- are suggested. The present invention also suggests alternative formulations and delivery systems...

Detailed Description

... invention proposes that the use of pharmaceutically acceptable co-solvents and potential penetration promoters in **cyclosporin**-containing **topical** treatment formulations may result in decreased or lost efficacy locally, but increased efficacy systemically, Therefore...

...formulations in the locally-treated tissues which extends into the systemic circulation. However, by lowering **cyclosporin** doses with such formulations, the potentially desired local result can be effected. In contradistinction, **topical cyclosporin** formulations without UT SUOT-4PTnuI:xOJ VsD Tlcn-rdo-4 Tle.19A9S Jo 9UO AU2...same, one advantage of the present invention over the prior art includes the fact that **topical** application of **cyclosporin** is effective in abrogating skin allograft rejection, inflammatory reactions and autoimmune, skin disorders, without interfering...

...are cyclosporins. Further,, in the case of steroid creams and ointments, a detrimental effect on **wound** healing and non specific immunity against infection may result from their use.

A further advantage...in this in vivo model, there were no gross indications of keratinocyte inhibition (i.e., **wound** healing and epidermal appearance were normal). Moreover, it appeared that there was no inherent toxicity...

...and by in vivo skin allograft rejection in the vehicle-treated graft,
Example 2
(Suggested **Topical** Formulations of **Cyclosporin**)
As discussed supra,, different conditions of the skin and other tissues will require different treatment...

...in order to achieve maximum efficacy. Therefore, the following formulations are provided as examples of **topical** compositions that have proven to be efficacious in a site-specific fashion in our studies,
a. Creme-Lotion Base **Topical** Formulation of **Cyclosporin** .

one composition of topical cyclosporin is a water-in oil creme emulsion and consists of...is likely that this is responsible for the observed systemic effects.

The fact that a **cyclosporin** dose reduction effects a localized anti-inflammatory mechanism argues strongly for a **cyclosporin** gradient being created in the target tissue which extended into the systemic circulation with this...

...of the more hydrophobic/lipophilic formulation experiments detailed herein. In the latter cases, at equivalent **topical cyclosporin** doses, the agent appeared to primarily localize within the target tissue, did not extend significantly...

...and possibly synergize the treatment of inflammatory diseases of the skin and to promote **wound** healing. Such **topical** formulations may also be used in conjunction with systemic treatment, albeit the systemic/ **topical** treatment modality is not required for said **topical** formulations to prove efficacious.

For example, in the case of a disease such as alopecia...

Claim

... the topical
composition is a spray.

18 A use according to Claim 7,, wherein the **topical**
composition comprises, in approximate amounts by weight:
a. 5-80% pharmaceutical carrier;
b. 5-50...

...el 1-5% penetration enhancer;
d, 0,1-20% emulsifier; and
el 0,2%-25% **cyclosporin** ;
19e A use according to Claim 18, @iherein the
cyclosporin is Cyclosporine A powder,
20e A method for inducing acceptance of organ or
tissue transplants by a host organism, comprising:
a. systemically administering a composition
containing **cyclosporin** in pharmaceutically
effective amounts, to the host organism;
b, locally administering a composition
containing **cyclosporin** in pharmaceutically
effective amounts to the transplanted or
grafted tissue or organ,, subsequent to said...

...initiating said systemic administration at the
time of allografting and discontinuing said systemic
administration once **wound** healing has occurred,
22* A method for testing treatment protocols,
comprising:
a, obtaining tissue from...

?

2/9/6 (Item 3 from file: 446)
DIALOG(R) File 446:IMS New Product Focus
(c) 2004 IMS Health & Affiliates. All rts. reserv.

00141640

Brand Name: **DEXAPANTHENOL**

New Product Launch Letter - 19960617

COMPANY INFORMATION:

Company Name:	Memphis
Parent Company:	Memphis

DRUG INFORMATION:

Launch Date:	1st Qtr 1996 (19960300)
Launch Country:	Egypt
Composition:	dexpantenol, 5%.
Number of Ingredients:	1
Therapeutic Class Code:	D3A (Cicatrizants)
Package/Price:	cream topical 20 g: EP 1.95 (RSP)
Dose Form:	cream topical
Indications on Pack:	In cases of wounds, burns, anal fissures, fissured nipples and dressing after operations, to enhance healing.

?

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 81-13-0 REGISTRY

CN Butanamide, 2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethyl-, (2R)- (9CI)
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Butanamide, 2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethyl-, (R)-

CN Butyramide, 2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethyl-, D-(+)- (8CI)

OTHER NAMES:

CN (+)-Panthenol

CN Alcopan 250

CN Bepanthen

CN Bepanthene

CN Bepantol

CN Cozyme

CN D(+)-.alpha.,.gamma.-Dihydroxy-N-(3-hydroxypropyl)-.beta.,.beta.-
dimethylbutyramide

CN D(+)-2,4-Dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutyramide

CN D(+)-Panthenol

CN D(+)-Pantothenyl alcohol

CN D-P-A Injection

CN D-Panthenol

CN d-Panthenol

CN d-Panthenol 50

CN d-Pantothenol

CN D-Pantothenyl alcohol

CN d-Pantothenyl alcohol

CN **Dexpanthenol**

CN Ilopan

CN Intrapan

CN Motilyn

CN NSC 302962

CN Panadon

CN Pantenyl

CN Panthenol

CN Panthenol, (+)-

CN Panthoderm

CN Pantol

CN Pantothenol

CN Pantothenyl alcohol

CN Propanolamine, N-pantoyl-

CN Provitamin B

CN Provitamin B5

CN Synapan

CN Thenalton

CN Urupan

CN Zentinic

FS STEREOSEARCH

DR 1113-70-8, 17307-32-3

MF C9 H19 N O4

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE,
HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*,
MSDS-OHS, NAPRALERT, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2,
USPATFULL

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

922 REFERENCES IN FILE CA (1907 TO DATE)
26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
926 REFERENCES IN FILE CAPLUS (1907 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)